Another European life sciences contender is crossing the Atlantic.
Agomab Therapeutics, the Belgium-based developer of fibrosis treatments, has set terms for its US IPO. The company is targeting a valuation of up to $828.5 million (“AGMB”), aiming to raise ~$212.5 million as the 2026 biotech listing window widens.
💊 THE LEAD ASSET: ONTUNISERTIB Investors are underwriting a specific solution to a surgical problem.
- ** The Drug:** Ontunisertib (AGMB-129), a gut-restricted ALK5 inhibitor.
- The Target: Fibrostenosing Crohn’s Disease. This is the severe scarring and narrowing of the gut that currently has few drug options and often forces patients into surgery.
- The Strategy: By focusing on “chronic fibrotic conditions,” Agomab is attacking the structural damage caused by inflammation, not just the inflammation itself.
📊 THE OFFERING:
- Range: $15 – $17 per ADS.
- Volume: 12.5 million shares.
- Underwriters: J.P. Morgan, Morgan Stanley, Leerink Partners, and Van Lanschot Kempen.
🌤️ MARKET THAW: Agomab joins Eikon Therapeutics and Veradermics in a busy January filing slate, signaling that the US IPO market has stabilized following the “extended October shutdown.”
💡 ANALYST TAKEAWAY: Fibrosis has historically been a graveyard for drug development, but it remains one of the largest untapped commercial opportunities in pharma. If Agomab’s localized approach (gut-restricted) can safely inhibit ALK5 without systemic toxicity, they aren’t just treating Crohn’s; they are validating a platform for reversing tissue scarring. A successful float here proves that US institutional appetite for high-science European biotech remains robust.
👇 Pharma Investors: Is targeting fibrosis the next major growth engine for I&I portfolios, or remains too risky compared to standard anti-inflammatories?